IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company"
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data
11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.
IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company"
IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company"
IntelGenx Closes $3.5 Million Public Offering
GlobeNewswire - Mon Dec 16, 2:35PM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
GlobeNewswire - Thu Dec 12, 7:05AM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights
GlobeNewswire - Fri Nov 08, 5:05AM CST
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"